Hesham Mohamed
About
Hesham Mohamed is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Hesham Mohamed has authored 121 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 33 papers in Pathology and Forensic Medicine and 28 papers in Genetics. Recurrent topics in Hesham Mohamed's work include Lymphoma Diagnosis and Treatment (30 papers), CAR-T cell therapy research (27 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Hesham Mohamed is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), CAR-T cell therapy research (27 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Hesham Mohamed collaborates with scholars based in United States, Spain and Italy. Hesham Mohamed's co-authors include Jörge E. Cortes, Giuseppe Saglio, Andreas Hochhaus, Hagop M. Kantarjian, Neil P. Shah, Charles A. Schiffer, Dong‐Wook Kim, Diane Healey, M. Brigid Bradley‐Garelik and Philippe Rousselot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Hesham Mohamed
85 papers receiving 1.2k citations
Peers
Hesham Mohamed
Valérie Coiteux France
Saengsuree Jootar Thailand
Robin Filshie Australia
Elias Jabbour United States
Donal P. McLornan United Kingdom
Enrico Montefusco Italy
Deepti Radia United Kingdom
Prajwal Boddu United States
G. Alimena Italy
Mieczysław Komarnicki Poland
Citations per year, relative to Hesham Mohamed Hesham Mohamed (= 1×)
peers
Valérie Coiteux
Countries citing papers authored by Hesham Mohamed
Since
Specialization
Citations
This map shows the geographic impact of Hesham Mohamed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hesham Mohamed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hesham Mohamed more than expected).
Fields of papers citing papers by Hesham Mohamed
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hesham Mohamed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hesham Mohamed. The network helps show where Hesham Mohamed may publish in the future.
Co-authorship network of co-authors of Hesham Mohamed
This figure shows the co-authorship network connecting the top 25 collaborators of Hesham Mohamed. A scholar is included among the top collaborators of Hesham Mohamed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hesham Mohamed. Hesham Mohamed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tresckow, Bastian von, Yuting Kuang, Jennifer Uyei, et al.. (2025). Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review. European Journal Of Haematology. 115(2). 104–116.
2.
Arnason, Jon, Matthew J. Matasar, Stefano Luminari, et al.. (2025). Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Advances. 9(23). 6130–6140.
3.
Mohamed, Hesham, et al.. (2025). Impact of nano zinc on hormonal profile, immunity and body/testicular measurements of Ossimi lambs. 39(1). 151–162.
4.
Keudell, Gottfried von, Eliza A. Hawkes, Cecilia Carpio, et al.. (2024). Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab. Blood. 144(Supplement 1). 3080–3080.
5.
Ayyappan, Sabarish, H. Miles Prince, Cecilia Carpio, et al.. (2024). Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study. Blood. 144(Supplement 1). 4486–4486.
6.
Moin, Afrasim, Sreeja Biswas Roy, Hesham Mohamed, & A. Arjuna. (2024). Medication-Induced Significant Bradycardia in a Fresh Lung Transplant Recipient: To Use or Not to Use?. A5940–A5940.
7.
Vitolo, Umberto, Michele Merli, Lalita Norasetthada, et al.. (2024). Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).. Journal of Clinical Oncology. 42(16_suppl). TPS7094–TPS7094.
8.
Birhiray, Ruemu, Stefano Luminari, Tae Min Kim, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).. Journal of Clinical Oncology. 42(16_suppl). TPS7096–TPS7096.
9.
Bansal, Sandhya, et al.. (2024). Late-Onset Exudative Pleural Effusions Without Concomitant Airway Obstruction or Lung Parenchymal Abnormalities: A Novel Presentation of Chronic Lung Allograft Dysfunction. Transplant International. 37. 12395–12395.
10.
Jagadeesh, Deepa, Silvana Novelli, Stefano Luminari, et al.. (2024). Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy. Blood. 144(Supplement 1). 7803–7803.
11.
Mohamed, Hesham, et al.. (2024). THE STORY OF THE UNREMITTING RASH IN A LUNG TRANSPLANT RECIPIENT. CHEST Journal. 166(4). A1146–A1147.
12.
Roy, Sreeja Biswas, et al.. (2024). Molded by Care: A Case of Endobronchial Aspergillosis Managed Conservatively in a Lung Transplant Recipient. The Journal of Heart and Lung Transplantation. 43(4). S486–S486.
13.
Baird, John H., Pim Mutsaers, Jeremy S. Abramson, et al.. (2023). Abstract CT129: Trial in progress: ATHENA-1 - a phase 1, open-label, first-in-human study to assess safety and tolerability of REGN5837 in combination with odronextamab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas. Cancer Research. 83(8_Supplement). CT129–CT129.
14.
Cho, Seok‐Goo, Tae Min Kim, Aafia Chaudhry, et al.. (2023). PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY. HemaSphere. 7(S3). e4155242–e4155242.
15.
Mohamed, Hesham, et al.. (2021). Bronchopleural Fistula as a Complication in a COVID-19 Patient Managed With Endobronchial Valves. Journal of Investigative Medicine High Impact Case Reports. 9. 1605860959–1605860959.
16.
Jouhi, Lauri, Hesham Mohamed, Antti Mäkitie, et al.. (2020). In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality. Oral Oncology. 107. 104778–104778.
17.
Mohamed, Hesham, Jaana Hagström, Lauri Jouhi, et al.. (2019). The expression and prognostic value of stem cell markers Bmi-1, HESC5:3, and HES77 in human papillomavirus–positive and –negative oropharyngeal squamous cell carcinoma. Tumor Biology. 41(3). 3726345647–3726345647.
18.
Sorsa, Timo, Lauri Jouhi, Taina Tervahartiala, et al.. (2019). High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer. Cancer Immunology Immunotherapy. 68(8). 1263–1272.
19.
Mohamed, Hesham, Katri Aro, Lauri Jouhi, et al.. (2018). Expression of hormone receptors in oropharyngeal squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 275(5). 1289–1300.
20.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Valérie Coiteux Breakdown of academic impact, for papers by Saengsuree Jootar Breakdown of academic impact, for papers by Robin Filshie Breakdown of academic impact, for papers by Elias Jabbour Breakdown of academic impact, for papers by Donal P. McLornan Breakdown of academic impact, for papers by Enrico Montefusco Breakdown of academic impact, for papers by Deepti Radia Breakdown of academic impact, for papers by Prajwal Boddu Breakdown of academic impact, for papers by G. Alimena Breakdown of academic impact, for papers by Mieczysław Komarnicki